Enclomifene

Enclomifene (INN, USAN) (developmental code names GTx-758, RMI-16289), also known as enclomiphene (BAN), is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that is under development for the treatment of hypogonadism and breast cancer.

Pharmacology

Enclomifene is a SERM, or an anti-estrogen, which decreases the effect of estrogen in the body. It is the trans-isomer of clomifene (clomiphene). Enclomifene constitutes about 70% of the mixture in clomifene, with the remaining 30% being composed of its cis-isomer, zuclomifene.

Medical Uses

Enclomifene is used for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. It is also being developed for use in the treatment of men with low testosterone levels who wish to preserve their fertility.

Side Effects

The most common side effects of enclomifene include headache, nausea, and in some cases, visual disturbances. These side effects are generally mild and temporary.

Development

Enclomifene was developed by GTx, Inc., a biopharmaceutical company based in Memphis, Tennessee. It is currently in the late stages of clinical development.

See Also

• Selective estrogen receptor modulator
• Clomifene
• Zuclomifene

References

Enclomifene Resources
Latest articles Most recent articles Ongoing trials	Wikipedia